What is Protalix Biother's earnings per share (EPS)?

Protalix Biother (PLX) reported diluted earnings per share of $0.04 for fiscal year 2024. This represents a -55.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Protalix Biother Financials

PLX

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Protalix Biother (PLX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 43/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Protalix Biother has an operating margin of 7.3%, meaning the company retains $7 of operating profit per $100 of revenue. This results in a moderate score of 39/100, indicating healthy but not exceptional operating efficiency. This is down from 16.0% the prior year.

Growth

Protalix Biother's revenue declined 18.5% year-over-year, from $65.5M to $53.4M. This contraction results in a growth score of 3/100.

Leverage

Protalix Biother carries a low D/E ratio of 0.70, meaning only $0.70 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 88/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Protalix Biother's current ratio of 2.34 indicates adequate short-term liquidity, earning a score of 44/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Protalix Biother has a free cash flow margin of 13.8%, earning a moderate score of 60/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Protalix Biother generates a 6.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 26/100. This is down from 24.8% the prior year.

Altman Z-Score Distress

-2.21

Protalix Biother scores -2.21, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($178.1M) relative to total liabilities ($30.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Neutral

4/9

Protalix Biother passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

2.96x

For every $1 of reported earnings, Protalix Biother generates $2.96 in operating cash flow ($8.7M OCF vs $2.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$53.4M

YoY-18.5%

5Y CAGR-0.5%

10Y CAGR+31.2%

Protalix Biother generated $53.4M in revenue in fiscal year 2024. This represents a decrease of 18.5% from the prior year.

EBITDA

$5.2M

YoY-55.2%

Protalix Biother's EBITDA was $5.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 55.2% from the prior year.

Net Income

$2.9M

YoY-64.7%

Protalix Biother reported $2.9M in net income in fiscal year 2024. This represents a decrease of 64.7% from the prior year.

EPS (Diluted)

$0.04

YoY-55.6%

Protalix Biother earned $0.04 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 55.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$7.4M

YoY+399.6%

Protalix Biother generated $7.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 399.6% from the prior year.

Cash & Debt

$19.8M

YoY-16.4%

5Y CAGR+2.1%

10Y CAGR-9.7%

Protalix Biother held $19.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

76M

YoY+4.0%

5Y CAGR+38.6%

Protalix Biother had 76M shares outstanding in fiscal year 2024. This represents an increase of 4.0% from the prior year.

Margins & Returns

Gross Margin

54.5%

YoY-10.5pp

5Y CAGR-25.6pp

10Y CAGR-27.7pp

Protalix Biother's gross margin was 54.5% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 10.5 percentage points from the prior year.

Operating Margin

7.3%

YoY-8.6pp

5Y CAGR+26.9pp

10Y CAGR+818.0pp

Protalix Biother's operating margin was 7.3% in fiscal year 2024, reflecting core business profitability. This is down 8.6 percentage points from the prior year.

Net Margin

5.5%

YoY-7.2pp

5Y CAGR+38.9pp

10Y CAGR+855.4pp

Protalix Biother's net profit margin was 5.5% in fiscal year 2024, showing the share of revenue converted to profit. This is down 7.2 percentage points from the prior year.

Return on Equity

6.8%

YoY-18.0pp

Protalix Biother's ROE was 6.8% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 18.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$13.0M

YoY-24.1%

5Y CAGR-21.9%

10Y CAGR-7.2%

Protalix Biother invested $13.0M in research and development in fiscal year 2024. This represents a decrease of 24.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$1.3M

YoY+11.6%

5Y CAGR+15.4%

10Y CAGR+5.0%

Protalix Biother invested $1.3M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 11.6% from the prior year.

PLX Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$53.4M-18.5%	$65.5M+37.5%	$47.6M+24.2%	$38.4M-39.0%	$62.9M+15.0%	$54.7M
Cost of Revenue	$24.3M+5.8%	$23.0M+17.3%	$19.6M+19.8%	$16.3M+50.4%	$10.9M-0.2%	$10.9M
Gross Profit	$29.1M-31.6%	$42.5M+51.6%	$28.0M+27.5%	$22.0M-57.7%	$52.0M+18.8%	$43.8M
R&D Expenses	$13.0M-24.1%	$17.1M-41.8%	$29.3M-1.3%	$29.7M-22.1%	$38.2M-14.5%	$44.6M
SG&A Expenses	$12.2M-18.5%	$15.0M+27.7%	$11.7M-8.0%	$12.7M+14.2%	$11.1M+12.6%	$9.9M
Operating Income	$3.9M-62.6%	$10.5M+180.4%	-$13.0M+36.4%	-$20.5M-855.1%	$2.7M+125.3%	-$10.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$1.2M+381.1%	$254K-52.1%	$530K	N/A	N/A	N/A
Net Income	$2.9M-64.7%	$8.3M+155.7%	-$14.9M+45.9%	-$27.6M-322.8%	-$6.5M+64.3%	-$18.3M
EPS (Diluted)	$0.04-55.6%	$0.09+129.0%	$-0.31+50.0%	$-0.62-181.8%	$-0.22+82.1%	$-1.23

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$17.9M+14.0%	$15.7M+54.8%	$10.1M-44.5%	$18.2M+1.4%	$18.0M+33.3%	$13.5M+259.5%	$3.7M-64.3%	$10.5M
Cost of Revenue	$8.3M+41.8%	$5.9M-28.2%	$8.2M+110.5%	$3.9M-53.6%	$8.4M-11.4%	$9.5M+263.4%	$2.6M-70.6%	$8.9M
Gross Profit	$9.5M-2.7%	$9.8M+406.4%	$1.9M-86.5%	$14.3M+49.5%	$9.6M+138.5%	$4.0M+250.6%	$1.1M-29.7%	$1.6M
R&D Expenses	$4.5M-25.5%	$6.0M+72.4%	$3.5M-15.7%	$4.1M+37.6%	$3.0M+1.2%	$3.0M+2.6%	$2.9M-6.9%	$3.1M
SG&A Expenses	$2.9M+11.6%	$2.6M+0.8%	$2.6M-13.2%	$3.0M+15.6%	$2.6M-25.5%	$3.5M+11.8%	$3.1M-24.8%	$4.1M
Operating Income	$2.1M+81.8%	$1.2M+128.3%	-$4.1M-157.5%	$7.2M+80.6%	$4.0M+264.4%	-$2.4M+50.0%	-$4.9M+13.5%	-$5.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$116K-123.3%	$497K+539.8%	-$113K-113.7%	$822K+35.4%	$607K+979.7%	-$69K+50.0%	-$138K+63.9%	-$382K
Net Income	$2.4M+1336.0%	$164K+104.5%	-$3.6M-155.7%	$6.5M+100.7%	$3.2M+246.9%	-$2.2M+52.1%	-$4.6M+24.0%	-$6.0M
EPS (Diluted)	$0.03	$0.00+100.0%	$-0.05	N/A	$0.03+200.0%	$-0.03+50.0%	$-0.06	N/A

PLX Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$73.4M-13.0%	$84.4M+51.4%	$55.8M-24.3%	$73.7M+8.4%	$67.9M+49.7%	$45.4M
Current Assets	$60.1M-14.1%	$69.9M+55.8%	$44.9M-27.2%	$61.7M+10.7%	$55.7M+71.6%	$32.5M
Cash & Equivalents	$19.8M-16.4%	$23.6M+38.1%	$17.1M-56.1%	$39.0M+113.4%	$18.3M+2.7%	$17.8M
Inventory	$21.2M+11.5%	$19.0M+13.3%	$16.8M-6.4%	$18.0M+37.2%	$13.1M+60.4%	$8.2M
Accounts Receivable	$2.9M-44.8%	$5.3M+15.0%	$4.6M+33.2%	$3.4M+72.1%	$2.0M-57.4%	$4.7M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$30.2M-40.6%	$50.9M-23.4%	$66.4M-16.7%	$79.7M-16.1%	$95.0M-17.9%	$115.7M
Current Liabilities	$25.6M-43.7%	$45.5M+40.4%	$32.4M-2.3%	$33.2M-61.6%	$86.5M+115.2%	$40.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$43.2M+28.7%	$33.6M+415.5%	-$10.6M-76.3%	-$6.0M+77.7%	-$27.0M+61.6%	-$70.3M
Retained Earnings	-$378.4M+0.8%	-$381.5M+2.1%	-$389.9M-4.0%	-$374.9M-7.9%	-$347.4M-1.9%	-$340.8M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$82.3M+4.8%	$78.5M+6.2%	$73.9M+0.6%	$73.4M+19.3%	$61.6M-32.7%	$91.5M+1.9%	$89.8M+6.4%	$84.4M
Current Assets	$66.5M+1.6%	$65.5M+8.2%	$60.5M+0.7%	$60.1M+25.5%	$47.9M-38.1%	$77.4M+2.6%	$75.4M+7.8%	$69.9M
Cash & Equivalents	$13.6M-23.7%	$17.9M-8.0%	$19.5M-1.5%	$19.8M-27.9%	$27.4M+17.1%	$23.4M-14.0%	$27.2M+15.1%	$23.6M
Inventory	$21.3M+0.6%	$21.1M+8.3%	$19.5M-8.2%	$21.2M+23.5%	$17.2M-17.0%	$20.7M-7.3%	$22.3M+17.3%	$19.0M
Accounts Receivable	$14.4M+52.8%	$9.4M+102.0%	$4.7M+60.7%	$2.9M+32.5%	$2.2M-78.3%	$10.1M+169.4%	$3.8M-28.7%	$5.3M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$29.4M+2.7%	$28.6M-0.4%	$28.7M-5.0%	$30.2M+3.7%	$29.1M-53.7%	$63.0M+4.9%	$60.0M+18.0%	$50.9M
Current Liabilities	$21.9M-8.9%	$24.1M-0.9%	$24.3M-5.1%	$25.6M+5.8%	$24.2M-58.2%	$58.0M+5.7%	$54.8M+20.4%	$45.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$52.9M+6.0%	$49.9M+10.4%	$45.2M+4.6%	$43.2M+33.2%	$32.4M+13.5%	$28.6M-4.0%	$29.8M-11.3%	$33.6M
Retained Earnings	N/A	N/A	N/A	-$378.4M	N/A	N/A	N/A	-$381.5M

PLX Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	$8.7M+758.1%	-$1.3M+94.7%	-$25.0M-143.1%	-$10.3M+60.6%	-$26.1M-34.9%	-$19.4M
Capital Expenditures	$1.3M+11.6%	$1.1M+83.0%	$628K-57.0%	$1.5M+122.7%	$655K+4.5%	$627K
Free Cash Flow	$7.4M+399.6%	-$2.5M+90.4%	-$25.6M-118.2%	-$11.7M+56.1%	-$26.8M-33.9%	-$20.0M
Investing Cash Flow	$4.2M+125.3%	-$16.7M-231.9%	-$5.0M-126.6%	$18.9M+194.8%	-$20.0M-2159.6%	-$883K
Financing Cash Flow	-$16.8M-168.1%	$24.7M+199.4%	$8.2M-31.8%	$12.1M-74.0%	$46.5M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$3.7M+28.7%	-$5.2M-3.5%	-$5.1M-226.7%	$4.0M-2.8%	$4.1M+213.7%	-$3.6M-186.2%	$4.2M+16.5%	$3.6M
Capital Expenditures	$498K+15.5%	$431K+40.8%	$306K-28.0%	$425K+388.5%	$87K-49.4%	$172K-71.2%	$598K+139.2%	$250K
Free Cash Flow	-$4.2M+25.3%	-$5.7M-5.6%	-$5.4M-250.4%	$3.6M-11.2%	$4.0M+206.2%	-$3.8M-205.3%	$3.6M+7.3%	$3.3M
Investing Cash Flow	-$504K-15.1%	-$438K-40.4%	-$312K+98.0%	-$15.3M-175.4%	$20.3M+11392.8%	-$180K+70.3%	-$606K-77.2%	-$342K
Financing Cash Flow	$0-100.0%	$4.1M-19.1%	$5.1M+40.0%	$3.6M	N/A	N/A	N/A	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PLX Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	54.5%-10.5pp	64.9%+6.0pp	58.9%+1.5pp	57.4%-25.3pp	82.7%+2.6pp	80.1%
Operating Margin	7.3%-8.6pp	16.0%+43.3pp	-27.3%+26.0pp	-53.4%-57.7pp	4.3%+23.9pp	-19.6%
Net Margin	5.5%-7.2pp	12.7%+44.0pp	-31.3%+40.6pp	-71.9%-61.5pp	-10.4%+23.0pp	-33.4%
Return on Equity	6.8%-18.0pp	24.8%	N/A	N/A	N/A	N/A
Return on Assets	4.0%-5.9pp	9.8%+36.6pp	-26.8%+10.7pp	-37.4%-27.8pp	-9.6%+30.7pp	-40.3%
Current Ratio	2.34+0.8	1.54+0.2	1.38-0.5	1.86+1.2	0.64-0.2	0.81
Debt-to-Equity	0.70-0.8	1.52+7.8	-6.24+7.0	-13.20-9.7	-3.51-1.9	-1.65
FCF Margin	13.8%+17.6pp	-3.8%+50.0pp	-53.8%-23.2pp	-30.6%+11.9pp	-42.5%-6.0pp	-36.5%

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	53.4%-9.1pp	62.5%+43.4pp	19.1%-59.6pp	78.7%+25.3pp	53.4%+23.5pp	29.8%-0.8pp	30.6%+15.0pp	15.5%
Operating Margin	11.9%+4.5pp	7.5%+48.5pp	-41.0%-80.6pp	39.6%+17.3pp	22.2%+40.2pp	-18.0%+111.6pp	-129.6%-76.0pp	-53.5%
Net Margin	13.2%+12.1pp	1.1%+36.8pp	-35.8%-71.4pp	35.6%+17.6pp	18.0%+34.4pp	-16.4%+106.3pp	-122.6%-65.0pp	-57.6%
Return on Equity	4.5%+4.1pp	0.3%+8.3pp	-8.0%-23.0pp	15.0%+5.0pp	10.0%+17.7pp	-7.7%+7.7pp	-15.4%+2.6pp	-18.0%
Return on Assets	2.9%+2.6pp	0.2%+5.1pp	-4.9%-13.8pp	8.8%+3.6pp	5.3%+7.7pp	-2.4%+2.7pp	-5.1%+2.0pp	-7.2%
Current Ratio	3.03+0.3	2.72+0.2	2.49+0.1	2.34+0.4	1.98+0.6	1.33-0.0	1.38-0.2	1.54
Debt-to-Equity	0.55-0.0	0.57-0.1	0.63-0.1	0.70-0.2	0.90-1.3	2.20+0.2	2.02+0.5	1.52
FCF Margin	-23.7%+12.5pp	-36.2%+16.9pp	-53.0%-72.6pp	19.6%-2.8pp	22.4%+50.4pp	-28.1%-123.8pp	95.8%+63.9pp	31.9%

Similar Companies

Inovio Pharmaceu INO

$78.1M

Avalo Therapeutics Inc AVTX

$370.8M

Orchestra BioMed Holdings Inc OBIO

$248.1M

Sangamo Therapeutics Inc SGMO

$115.4M

Seres Therapeutics Inc MCRB

$84.5M

Frequently Asked Questions

What is Protalix Biother's annual revenue?

Protalix Biother (PLX) reported $53.4M in total revenue for fiscal year 2024. This represents a -18.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Protalix Biother's revenue growing?

Protalix Biother (PLX) revenue declined by 18.5% year-over-year, from $65.5M to $53.4M in fiscal year 2024.

Is Protalix Biother profitable?

Yes, Protalix Biother (PLX) reported a net income of $2.9M in fiscal year 2024, with a net profit margin of 5.5%.

What is Protalix Biother's EBITDA?

Protalix Biother (PLX) had EBITDA of $5.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Protalix Biother's gross margin?

Protalix Biother (PLX) had a gross margin of 54.5% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Protalix Biother's operating margin?

Protalix Biother (PLX) had an operating margin of 7.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Protalix Biother's net profit margin?

Protalix Biother (PLX) had a net profit margin of 5.5% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Protalix Biother's return on equity (ROE)?

Protalix Biother (PLX) has a return on equity of 6.8% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Protalix Biother's free cash flow?

Protalix Biother (PLX) generated $7.4M in free cash flow during fiscal year 2024. This represents a 399.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Protalix Biother's operating cash flow?

Protalix Biother (PLX) generated $8.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Protalix Biother's total assets?

Protalix Biother (PLX) had $73.4M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Protalix Biother's capital expenditures?

Protalix Biother (PLX) invested $1.3M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Protalix Biother spend on research and development?

Protalix Biother (PLX) invested $13.0M in research and development during fiscal year 2024.

How many shares does Protalix Biother have outstanding?

Protalix Biother (PLX) had 76M shares outstanding as of fiscal year 2024.

What is Protalix Biother's current ratio?

Protalix Biother (PLX) had a current ratio of 2.34 as of fiscal year 2024, which is generally considered healthy.

What is Protalix Biother's debt-to-equity ratio?

Protalix Biother (PLX) had a debt-to-equity ratio of 0.70 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Protalix Biother's return on assets (ROA)?

Protalix Biother (PLX) had a return on assets of 4.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Protalix Biother's Altman Z-Score?

Protalix Biother (PLX) has an Altman Z-Score of -2.21, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Protalix Biother's Piotroski F-Score?

Protalix Biother (PLX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Protalix Biother's earnings high quality?

Protalix Biother (PLX) has an earnings quality ratio of 2.96x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Protalix Biother?

Protalix Biother (PLX) scores 43 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.